- Home
- MNY vs NRXP Comparison
MNY vs NRXP Comparison
Compare MNY & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNY
- NRXP
- Stock Information
- Founded
- MNY 2014
- NRXP 2015
- Country
- MNY Singapore
- NRXP United States
- Employees
- MNY N/A
- NRXP N/A
- Industry
- MNY
- NRXP Biotechnology: Pharmaceutical Preparations
- Sector
- MNY
- NRXP Health Care
- Exchange
- MNY Nasdaq
- NRXP Nasdaq
- Market Cap
- MNY 40.6M
- NRXP 34.7M
- IPO Year
- MNY N/A
- NRXP N/A
- Fundamental
- Price
- MNY $0.76
- NRXP $1.90
- Analyst Decision
- MNY
- NRXP Strong Buy
- Analyst Count
- MNY 0
- NRXP 3
- Target Price
- MNY N/A
- NRXP $31.67
- AVG Volume (30 Days)
- MNY 39.4K
- NRXP 182.2K
- Earning Date
- MNY 04-28-2025
- NRXP 03-17-2025
- Dividend Yield
- MNY N/A
- NRXP N/A
- EPS Growth
- MNY N/A
- NRXP N/A
- EPS
- MNY N/A
- NRXP N/A
- Revenue
- MNY $90,185,081.00
- NRXP N/A
- Revenue This Year
- MNY $18.50
- NRXP N/A
- Revenue Next Year
- MNY $24.83
- NRXP N/A
- P/E Ratio
- MNY N/A
- NRXP N/A
- Revenue Growth
- MNY 24.60
- NRXP N/A
- 52 Week Low
- MNY $0.65
- NRXP $1.10
- 52 Week High
- MNY $2.75
- NRXP $6.01
- Technical
- Relative Strength Index (RSI)
- MNY 39.55
- NRXP 43.02
- Support Level
- MNY $0.65
- NRXP $1.95
- Resistance Level
- MNY $0.82
- NRXP $2.12
- Average True Range (ATR)
- MNY 0.06
- NRXP 0.17
- MACD
- MNY 0.01
- NRXP 0.02
- Stochastic Oscillator
- MNY 59.75
- NRXP 23.93
About MNY MoneyHero Limited
MoneyHero Ltd is a personal finance aggregation and comparison company in Greater Southeast Asia. The firm is involved in the operation of online financial comparison platforms and related services for credit cards, personal loans, mortgages, insurance, and other financial products, connecting the providers of these products with well-matched and ready-to-transact consumers and generating revenue directly from these providers for placing their products on its platforms and providing insurance brokerage, marketing and events-related services.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.